Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial

Shabbar Jaffar, Barbara Amuron, Susan Foster, Josephine Birungi, Jonathan Levin, Geoffrey Namara, Christine Nabiryo, Nicaise Ndembi, Rosette Kyomuhangi, Alex Opio, Rebecca Bunnell, Jordan W Tappero, Jonathan Mermin, Alex Coutinho, Heiner Grosskurth, Jinja trial team, Shabbar Jaffar, Barbara Amuron, Susan Foster, Josephine Birungi, Jonathan Levin, Geoffrey Namara, Christine Nabiryo, Nicaise Ndembi, Rosette Kyomuhangi, Alex Opio, Rebecca Bunnell, Jordan W Tappero, Jonathan Mermin, Alex Coutinho, Heiner Grosskurth, Jinja trial team

Abstract

Background: Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care.

Methods: We undertook a cluster-randomised equivalence trial in Jinja, Uganda. 44 geographical areas in nine strata, defined according to ratio of urban and rural participants and distance from the clinic, were randomised to home-based or facility-based care by drawing sealed cards from a box. The trial was integrated into normal service delivery. All patients with WHO stage IV or late stage III disease or CD4-cell counts fewer than 200 cells per microL who started antiretroviral therapy between Feb 15, 2005, and Dec 19, 2006, were eligible, apart from those living on islands. Follow-up continued until Jan 31, 2009. The primary endpoint was virological failure, defined as RNA more than 500 copies per mL after 6 months of treatment. The margin of equivalence was 9% (equivalence limits 0.69-1.45). Analyses were by intention to treat and adjusted for baseline CD4-cell count and study stratum. This trial is registered at http://isrctn.org, number ISRCTN 17184129.

Findings: 859 patients (22 clusters) were randomly assigned to home and 594 (22 clusters) to facility care. During the first year, 93 (11%) receiving home care and 66 (11%) receiving facility care died, 29 (3%) receiving home and 36 (6%) receiving facility care withdrew, and 8 (1%) receiving home and 9 (2%) receiving facility care were lost to follow-up. 117 of 729 (16%) in home care had virological failure versus 80 of 483 (17%) in facility care: rates per 100 person-years were 8.19 (95% CI 6.84-9.82) for home and 8.67 (6.96-10.79) for facility care (rate ratio [RR] 1.04, 0.78-1.40; equivalence shown). Two patients from each group were immediately lost to follow-up. Mortality rates were similar between groups (0.95 [0.71-1.28]). 97 of 857 (11%) patients in home and 75 of 592 (13%) in facility care were admitted at least once (0.91, 0.64-1.28).

Interpretation: This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care.

Copyright 2009 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile TASO=The AIDS Support Organisation.
Figure 2
Figure 2
Kaplan-Meier curve of HIV-RNA virological suppression (A) and survival (B)
Figure 3
Figure 3
Median (IQR) CD4-cell counts
Figure 4
Figure 4
Proportion (95% CI) of patients reporting complete adherence in the past 28 days

References

    1. WHO . Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. Report by the Secretariat. WHO; Geneva: 2008.
    1. United Nations General Assembly . Political Declaration on HIV/AIDS. United Nations; New York: 2006. (United Nations General Assembly document 60/262. (accessed May 1, 2009).
    1. WHO . The World Health Report: primary care now more than ever. WHO; Geneva: 2008.
    1. Hardon AP, Akurut D, Comoro C. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19:658–665.
    1. Ware NC, Idoko J, Kaaya S. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009;6:e11.
    1. WHO . Treat, train, retain. Task shifting: global recommendations and guidelines. WHO; Geneva: 2007.
    1. Gilks CF, Crowley S, Ekpini R. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368:505–510.
    1. Ferradini L, Jeannin A, Pinoges L. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335–1342.
    1. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet. 2006;367:1870–1872.
    1. Stringer JS, Zulu I, Levy J. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782–793.
    1. Gimbel-Sherr SO, Micek MA, Gimbel-Sherr KH. Using nurses to identify HAART eligible patients in the Republic of Mozambique: results of a time series analysis. Hum Resour Health. 2007;5:7.
    1. Miles K, Clutterbuck DJ, Seitio O, Sebego M, Riley A. Antiretroviral treatment roll-out in a resource-constrained setting: capitalizing on nursing resources in Botswana. Bull World Health Organ. 2007;85:555–560.
    1. Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis. 2007;196(suppl 3):464–468.
    1. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.
    1. Zachariah R, Ford N, Philips M. Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2009;103:549–558.
    1. Mermin J, Were W, Ekwaru JP. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet. 2008;371:752–759.
    1. Weidle PJ, Wamai N, Solberg P. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006;368:1587–1594.
    1. Amuron B, Coutinho A, Grosskurth H. A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings. Open AIDS J. 2007;1:21–27.
    1. Jaffar S, Amuron B, Birungi J. Integrating research into routine service delivery in an antiretroviral treatment programme: lessons learnt from a cluster randomized trial comparing strategies of HIV care in Jinja, Uganda. Trop Med Int Health. 2008;13:795–800.
    1. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20:1391–1399.
    1. Coetzee D, Hildebrand K, Boulle A. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887–895.
    1. Laurent C, Diakhate N, Gueye NF. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363–1370.
    1. WHO International Statistical Classification of Diseases and Related Health Problems, 10th revision, version for. 2007. (accessed Aug 10, 2009).
    1. Etard JF, Ndiaye I, Thierry-Mieg M. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181–1189.
    1. Marazzi MC, Liotta G, Germano P. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses. 2008;24:555–560.
    1. Toure S, Kouadio B, Seyler C. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22:873–882.
    1. Braitstein P, Brinkhof MW, Dabis F, for the Antiretroviral Therapy in Lower Income Countries Collaboration Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817–824.
    1. Fielding KL, Charalambous S, Stenson AL. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis. 2008;8:93.
    1. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897–1908.
    1. Medina-Lara A, Kigozi J, Amurwon J. Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring anti-retroviral therapy in Uganda and Zimbabwe (DART Trial). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention Cape Town. International AIDS Society, 2009. (accessed July 1, 2009).
    1. Amuron B, Namara G, Birungi J. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.
    1. Jaffar S, Leach A, Hall AJ. Preparation for a pneumococcal vaccine trial in The Gambia: individual or community randomisation? Vaccine. 1999;18:633–640.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir